Goldman Sachs’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Goldman Sachs’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-369	Closed	-$9K	–	7126
2017 Q1	$9K	Buy	369 +242	+191%	+$6.05K	﹤0.01%	6625
2016 Q4	$4K	Buy	+127	New	+$5.42K	﹤0.01%	6826
2016 Q3	–	Sell	-102	Closed	-$4K	–	7334
2016 Q2	$4K	Sell	102 -9,875	-99%	-$538K	﹤0.01%	6950
2016 Q1	$657K	Buy	+9,977	New	+$521K	﹤0.01%	4469
2014 Q3	–	Sell	-19,065	Closed	-$1.09M	–	7386
2014 Q2	$1.09M	Buy	+19,065	New	+$968K	﹤0.01%	4611

Goldman Sachs's MACK Position: Q3 2024 in Review

Goldman Sachs sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2024, closing a stake of 29,807 shares — an estimated $451K sold.

Goldman Sachs first reported a position in MACK in Q2 2013 and held it in 32 quarters. The position peaked at $4.8M in Q2 2014. 2 funds tracked by Wall St. Rank hold MACK as of Q3 2024.

Goldman Sachs reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
Goldman Sachs sold 29,807 Merrimack Pharmaceuticals, Inc. shares in Q3 2024, an estimated $451K.
Goldman Sachs first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
Goldman Sachs's Merrimack Pharmaceuticals, Inc. position peaked at $4.8M in Q2 2014.
2 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.